Physician profile
Amanda Hathaway
NPI 1225322431
$158,569.56
in general payments reported to CMS, 2019-2025
76 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $28K · 2021: $21K · 2022: $28K · 2023: $23K · 2024: $23K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $7,275 · Travel and Lodging: $4,348 · Consulting Fee: $3,300 · Long Term Medical Supply Or Device Loan: $2,165 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,100.00 |
| Food and Beverage | $7,274.82 |
| Travel and Lodging | $4,348.12 |
| Consulting Fee | $3,300.00 |
| Long Term Medical Supply Or Device Loan | $2,165.10 |
| Education | $117.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $114,163.09 | 2019-2025 | Verzenio, Jaypirca |
| Alexion Pharmaceuticals, INC. | $15,668.74 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $9,266.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,406.81 | 2019-2025 | Imfinzi, Truqap, Lynparza |
| Immunomedics, INC. | $2,200.00 | 2020 | |
| Gilead Sciences, INC. | $1,942.50 | 2021-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $1,500.00 | 2021 | |
| Daiichi Sankyo INC. | $1,468.72 | 2019-2025 | Enhertu |
| Beigene USA, INC. | $760.95 | 2024-2025 | Brukinsa, Tevimbra |
| Janssen Biotech, INC. | $663.96 | 2019-2025 | Darzalex, Erleada, Talvey |
| Merck Sharp & Dohme LLC | $642.95 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $619.04 | 2019-2025 | |
| Genentech USA, INC. | $565.74 | 2019-2025 | Polivy, Phesgo, Itovebi |
| Abbvie INC. | $390.05 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $332.47 | 2019-2024 | Opdualag |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $332.39 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Celgene Corporation | $298.08 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Amgen INC. | $258.59 | 2019-2024 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $257.84 | 2019-2025 | |
| Puma Biotechnology, INC. | $225.74 | 2019-2025 | Nerlynx |
| Pharmacyclics LLC, An Abbvie Company | $222.17 | 2019-2023 | Imbruvica |
| Genzyme Corporation | $214.80 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $207.43 | 2021-2024 | Libtayo |
| Astellas Pharma US INC | $207.25 | 2019-2025 | Vyloy |
| Eisai INC. | $205.16 | 2019-2024 | |
| Sobi, INC | $173.29 | 2024-2025 | |
| Seagen INC. | $166.11 | 2020-2025 | Tivdak, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $161.53 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Stemline Therapeutics INC. | $158.08 | 2023-2025 | Orserdu |
| Incyte Corporation | $147.01 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Exelixis INC. | $106.70 | 2019-2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $105.49 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Kyowa Kirin, INC. | $99.77 | 2019-2024 | Poteligeo |
| Pharmaessentia USA Corporation | $99.75 | 2025 | Besremi |
| Jazz Pharmaceuticals INC. | $90.80 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $82.70 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $77.16 | 2024-2025 | Onivyde |
| Sumitomo Pharma America, INC. | $61.37 | 2024-2025 | Orgovyx |
| Iovance Biotherapeutics, INC. | $58.31 | 2025 | Amtagvi |
| Genmab U.S., INC. | $53.73 | 2024 | Epkinly |
| Dendreon Pharmaceuticals LLC | $52.88 | 2023-2024 | Provenge |
| Beone Medicines USA, INC. | $47.91 | 2025 | Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.26 | 2022-2023 | Gilotrif |
| Ge Healthcare | $44.90 | 2021 | |
| Servier Pharmaceuticals LLC | $44.51 | 2024-2025 | |
| Taiho Oncology, INC. | $43.64 | 2019-2023 | |
| Array Biopharma INC | $41.96 | 2022-2025 | Mektovi, Tukysa, Braftovi |
| Kite Pharma, INC. | $39.78 | 2022-2025 | Yescarta |
| G1 Therapeutics, INC. | $39.58 | 2023 | Cosela |
| Adaptive Biotechnologies Corporation | $36.68 | 2023 | Clonoseq |
| Clovis Oncology, INC. | $36.18 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $35.39 | 2019-2020 | |
| Spectrum Pharmaceuticals INC. | $34.30 | 2024-2025 | Rolvedon |
| Emd Serono, INC. | $31.97 | 2023-2024 | Tepmetko |
| Karyopharm Therapeutics INC. | $27.61 | 2025 | Xpovio |
| Tempus Ai, INC | $25.96 | 2025 | Xt Cdx |
| Blueprint Medicines Corporation | $24.06 | 2023 | Ayvakit |
| Sirtex Medical INC | $22.96 | 2020 | |
| Recordati_rare_diseases_inc. | $19.88 | 2024 | Sylvant |
| Cti Biopharma Corp. | $18.04 | 2023 | Vonjo |
| Tersera Therapeutics LLC | $17.90 | 2022 | |
| Deciphera Pharmaceuticals INC. | $17.51 | 2023 | Qinlock |
| Acrotech Biopharma INC. | $16.64 | 2025 | Beleodaq |
| Fortovia Therapeutics, INC. | $15.68 | 2019 | |
| Dova Pharmaceuticals | $15.26 | 2020 | |
| Accord Healthcare, INC. | $15.21 | 2025 | |
| Apellis Pharmaceuticals, INC. | $14.87 | 2025 | Empaveli |
| Mirati Therapeutics, INC. | $14.83 | 2024 | Krazati |
| Helsinn Therapeutics (U.S.), INC. | $14.17 | 2019 | |
| Octapharma USA, INC. | $13.66 | 2025 | Octagam Immune Globulin (Human) |
| Morphosys, US INC. | $13.45 | 2023 | Monjuvi |
| Verastem, INC. | $12.46 | 2019 | |
| Secura Bio, INC. | $11.28 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$475.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hathaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.